On Invalid Date, Rapt Therapeutics (NASDAQ: RAPT) reported Q1 2024 earnings per share (EPS) of -$0.79, up 3.95% year over year. Total Rapt Therapeutics earnings for the quarter were -$30.52 million. In the same quarter last year, Rapt Therapeutics's earnings per share (EPS) was -$0.76.
As of Q2 2024, Rapt Therapeutics's earnings has grown year over year. Rapt Therapeutics's earnings in the past year totalled -$118.05 million.
What was RAPT's revenue last quarter?
On Invalid Date, Rapt Therapeutics (NASDAQ: RAPT) reported Q1 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Rapt Therapeutics's revenue was $0.00.
What was RAPT's revenue growth in the past year?
As of Q2 2024, Rapt Therapeutics's revenue has grown -100% year over year. This is 182.96 percentage points lower than the US Biotechnology industry revenue growth rate of 82.96%. Rapt Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.